loader from loading.io

Addressing Extracellular Matrix Breakdown That Leads to Age-Related Diseases with Dr. Sherif Idriss Elastin Biosciences TRANSCRIPT

Empowered Patient Podcast

Release Date: 09/24/2024

Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx TRANSCRIPT show art Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx TRANSCRIPT

Empowered Patient Podcast

Michael Palladino, VP of Sales and Clinical Solutions at OptimizeRx, is utilizing AI to educate patients and providers, promoting shared decision-making about which medications are most likely to yield the best health outcomes. The goal is to combat information overload by precisely targeting education to specific patients and delivering that information on the patient's preferred media delivery platform.  Technology-driven nudges deliver timely information, reminders about upcoming appointments, and address medication adherence issues.  Michael explains, "So OptimizeRx is a health...

info_outline
Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx show art Using AI to Connect Patients with the Right Medications with Michael Palladino OptimizeRx

Empowered Patient Podcast

Michael Palladino, VP of Sales and Clinical Solutions at OptimizeRx, is utilizing AI to educate patients and providers, promoting shared decision-making about which medications are most likely to yield the best health outcomes. The goal is to combat information overload by precisely targeting education to specific patients and delivering that information on the patient's preferred media delivery platform.  Technology-driven nudges deliver timely information, reminders about upcoming appointments, and address medication adherence issues.  Michael explains, "So OptimizeRx is a health...

info_outline
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion TRANSCRIPT show art Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion TRANSCRIPT

Empowered Patient Podcast

Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting.  Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...

info_outline
Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion show art Why Hospital Printers Have Become Targets for Cybercriminals with Jim LaRoe Symphion

Empowered Patient Podcast

Jim LaRoe, CEO of Symphion, highlights an often overlooked cybersecurity threat posed by network-connected printers in a hospital setting.  Modern printers are complex devices with numerous features that create vulnerabilities and potential access points to patient and hospital data for cybercriminals, yet they are generally managed outside of the IT security environment. The first step in ensuring printer security is to determine the number of printing devices on the network, their locations, and their configurations. Additionally, it is essential to ask the IT team to demonstrate...

info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech TRANSCRIPT show art How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech TRANSCRIPT

Empowered Patient Podcast

Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...

info_outline
How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech show art How Laboratory Robots Are Transforming Hydrogel Testing with Sinan Gölhan GelTech

Empowered Patient Podcast

Sinan Gölhan, Founder and CEO of GelTech, describes the characteristics and applications for hydrogels, which are bio-friendly, super-absorbent materials similar to natural tissue. In cancer treatments, hydrogels offer a way to deliver chemotherapy drugs directly to a tumor, which can significantly increase the accuracy and efficacy of the drug. GelTech has developed a robotic instrument to streamline the time-consuming testing process for new hydrogel treatments, automating repetitive actions, reducing inconsistencies, and enabling 24/7 testing capabilities. Sinan explains, "You could think...

info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT show art Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx TRANSCRIPT

Empowered Patient Podcast

Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...

info_outline
Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx show art Treating Autoimmune-Driven Dry Eye Disease with Immune Modulator with Elizabeth Jeffords Iolyx

Empowered Patient Podcast

Elizabeth Jeffords, CEO and President of Iolyx Therapeutics, discusses dry eye disease and its connection to autoimmune conditions. The company's novel therapeutic topical immune modulator is designed to treat the root inflammation in the eye, which systemic drugs often fail to reach due to the blood-retina barrier. Patients with dry eye disease often have multiple comorbidities and are excluded from clinical trials, making this research even more significant in finding treatments for a growing population. Elizabeth explains, "Some people have physical dry eye, i.e., they have a dysfunction...

info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked  to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics TRANSCRIPT show art Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics TRANSCRIPT

Empowered Patient Podcast

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...

info_outline
Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics show art Using AI in Drug Development to Protect Brain Enzyme Linked to Parkinson’s Disease Progression with Gene Mack Gain Therapeutics

Empowered Patient Podcast

Gene Mack, CEO and President of Gain Therapeutics, is combining AI-powered drug discovery with the development of allosteric modulators, drugs that bind to unique sites on proteins. The company's AI platform, Magellan, is crucial for accelerating drug discovery by reducing the time for computational screening of potential drug compounds.  Their lead compound is showing promising results as a potential disease-modifying therapy for Parkinson's disease, aiming to halt the progression of the disease rather than just treating symptoms. Gene explains, "So allosteric modulators of protein,...

info_outline
 
More Episodes

Dr. Sherif Idriss is the CEO of Elastin Biosciences, a company focused on targeting aging-related diseases by restoring elastin, a key protein in the extracellular matrix that provides elasticity and resilience to organs and tissues. They are developing small molecule therapies for diseases linked to elastin deficiency, including Williams syndrome and abdominal aortic aneurysm. As elastin degrades over time due to aging, it leads to loss of tissue structural integrity and function, contributing to numerous age-related diseases.  

Sherif explains, "One of the hallmarks of aging is the loss of the extracellular matrix, which is composed of several proteins. Collagen is quite famous, but also elastin is the other major protein that is responsible for the elasticity of the different organs. For example, in our skin, the loss of elastin is associated with us looking older and having all the aging signs and wrinkles on the skin. If you imagine that there are other organs inside that we don’t visually see, then you have also the blood vessels, the lungs, a lot of the connective tissue. The extracellular matrix proteins and elastin itself are also aging in the same way and have their own form of damage one way or another. All of this contributes to aging and aging-related diseases as well."

"Another kind of disease is the category of rare diseases. In this case, we aim to target Williams syndrome, a rare disease characterized by a genetic partial deletion of around 26 genes. One of these genes is elastin itself, so some genetic material is still there, but there is not enough. We would like to try to push the elastin production up in Williams syndrome, and this would help rectify a lot of the disease issues, particularly when it comes to the cardiovascular system because Williams syndrome patients have quite a lot of issues with the cardiovascular system from birth and all through life."

#ElastinBiosciences #Aging #AgingRelatedDiseases #Elastin #WilliamsSyndrome 

elastin-biosciences.com

Listen to the podcast here

Elastin